We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Panel Votes Down NicOx Drug, Asks for More Safety Studies
FDA Panel Votes Down NicOx Drug, Asks for More Safety Studies
May 14, 2010
A combined FDA advisory panel voted 16–1, with one abstention, to recommend against approval of NicOx’s naproxcinod, an osteoarthritis pain drug designed to be superior to current therapies.